Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study

Introduction Previously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI‐DS) and Alzheimer's disease (DS‐AD) from those cognitively stable (CS). Metho...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimer's & dementia : diagnosis, assessment & disease monitoring assessment & disease monitoring, 2020, Vol.12 (1), p.e12039-n/a
Main Authors: Petersen, Melissa E., Zhang, Fan, Schupf, Nicole, Krinsky‐McHale, Sharon J., Hall, James, Mapstone, Mark, Cheema, Amrita, Silverman, Wayne, Lott, Ira, Rafii, Michael S., Handen, Benjamin, Klunk, William, Head, Elizabeth, Christian, Brad, Foroud, Tatiana, Lai, Florence, Rosas, H. Diana, Zaman, Shahid, Ances, Beau M., Wang, Mei‐Cheng, Tycko, Benjamin, Lee, Joseph H., O'Bryant, Sid
Format: Article
Language:English
Subjects:
Accuracy
Age
Alzheimer's disease
Biomarkers
Clinical trials
Cognitive ability
Consortia
Cytokines
Dementia
Down syndrome
Neurodegeneration
Peptides
Plasma
Population
Proteins
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Previously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI‐DS) and Alzheimer's disease (DS‐AD) from those cognitively stable (CS). Methods Data were analyzed on n = 305 (n = 225 CS; n = 44 MCI‐DS; n = 36 DS‐AD) enrolled in the Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS). Results Distinguishing MCI‐DS from CS, the serum profile produced an area under the curve (AUC) = 0.95 (sensitivity [SN] = 0.91; specificity [SP] = 0.99) and an AUC = 0.98 (SN = 0.96; SP = 0.97) for plasma when using an optimized cut‐off score. Distinguishing DS‐AD from CS, the serum profile produced an AUC = 0.93 (SN = 0.81; SP = 0.99) and an AUC = 0.95 (SN = 0.86; SP = 1.0) for plasma when using an optimized cut‐off score. AUC remained unchanged to slightly improved when age and sex were included. Eotaxin3, interleukin (IL)‐10, C‐reactive protein, IL‐18, serum amyloid A , and FABP3 correlated fractions at r2 > = 0.90. Discussion Proteomic profiles showed excellent detection accuracy for MCI‐DS and DS‐AD.
ISSN:2352-8729
2352-8729
DOI:10.1002/dad2.12039